# Kiniksa Pharmaceuticals International, plc (KNSA)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $4.07B  
**Price:** $51.58 (+4.69%)

> Kiniksa Pharmaceuticals International, plc is a global biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapies for patients with serious unmet medical needs, particularly in cardiovascular and inflammatory diseases. Its lead product, ARCALYST (rilonacept), is an interleukin-1 inhibitor approved as the first and only FDA-approved treatment for recurrent pericarditis, an inflammatory cardiovascular condition causing debilitating chest pain and inflammation. The company advances a robust pipeline of clinical-stage assets, including vixarelimab, a monoclonal antibody in Phase 2b trials for prurigo nodularis, a chronic inflammatory skin disease, and KPL-387, advancing toward Phase 2/3 trials in recurrent pericarditis for potential monthly dosing. Kiniksa emphasizes immune modulation therapies with strong biologic rationale, targeting underserved conditions across multiple therapeutic categories. Through strategic partnerships, such as collaborations for commercialization in the Asia Pacific region and licensing agreements for global development, Kiniksa expands access to its innovative treatments worldwide. Founded in 2015, the company is headquartered in Hamilton, Bermuda, and led by a seasoned leadership team focused on patient-centric innovation in biopharmaceuticals.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $678M | $600M | $77M | $59M | $0.75 |
| 2024 | $423M | $362M | -$46M | -$43M | $-0.60 |
| 2023 | $270M | $237M | -$25M | $14M | $0.20 |
| 2022 | $220M | $197M | $10M | $183M | $2.60 |
| 2021 | $39M | $29M | -$157M | -$158M | $-2.30 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $764M | $196M | $568M | $166M | — |
| 2024 | $581M | $142M | $438M | $184M | — |
| 2023 | $526M | $87M | $439M | $108M | — |
| 2022 | $460M | $64M | $396M | $123M | — |
| 2021 | $233M | $48M | $185M | $122M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $138M | $2M | $136M |
| 2024 | $26M | $277,000 | $25M |
| 2023 | $13M | $130,000 | $13M |
| 2022 | $6M | $105,000 | $6M |
| 2021 | -$126M | $415,000 | -$127M |
| 2020 | -$137M | $283,000 | -$137M |
| 2019 | -$158M | $3M | -$162M |
| 2018 | -$81M | $5M | -$86M |
| 2017 | -$50M | $69,000 | -$50M |

Source: [CompaniesByCap](https://companiesbycap.com/company/KNSA)